Sorafenib inhibits HCC through the inhibition of vascular endothelial growth factor (VEGF) and partly through the inhibition of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) at the level of RAF [5,6]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.